In this process, cancer cells receive multiple copies of the genome. This in turn increases genetic complexity, allowing cells to adapt more quickly and develop resistance mechanisms against drugs.

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER PR Newswire THOUSAND OAKS, Calif., June 30, 2025 ...

Our data at SITC 2023 demonstrates that Pin1 is a promising cancer–fibroblast target to pursue for therapeutic interventions,” said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences.